25G-NBOMe

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 11:31, 21 June 2020 (Infobox drug: fix parameter name(s)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

25G-NBOMe
Clinical data
ATC code
  • none
Legal status
Legal status
Identifiers
  • 2-(2,5-dimethoxy-3,4-dimethylphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC20H27NO3
Molar mass329.4 g·mol−1
3D model (JSmol)
  • CC1=C(C=C(C(=C1C)OC)CCNCC2=CC=CC=C2OC)OC
  • InChI=1S/C20H27NO3/c1-14-15(2)20(24-5)16(12-19(14)23-4)10-11-21-13-17-8-6-7-9-18(17)22-3/h6-9,12,21H,10-11,13H2,1-5H3
  • Key:VDAUMFACIMNTDA-UHFFFAOYSA-N

25G-NBOMe (NBOMe-2C-G) is a derivative of the phenethylamine hallucinogen 2C-G, which acts as a highly potent partial agonist for the human 5-HT2A receptor.[1]

Legality

Sweden

The Riksdag added 25G-NBOMe to Narcotic Drugs Punishments Act under swedish schedule I ("substances, plant materials and fungi which normally do not have medical use") as of January 16, 2015, published by Medical Products Agency (MPA) in regulation LVFS 2014:11 listed as 25G-NBOMe, and 2-(2,5-dimetoxi-3,4-dimetylfenyl)-N-(2-metoxibensyl)etanamin.[2]

United Kingdom

This substance is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause in the Misuse of Drugs Act 1971.[3]

See also

References

  1. ^ [1][permanent dead link]
  2. ^ "Archived copy" (PDF). Archived from the original (PDF) on 2015-03-16. Retrieved 2017-04-21.{{cite web}}: CS1 maint: archived copy as title (link)
  3. ^ "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Statutory Instruments 2014 No. 1106. www.legislation.gov.uk.